◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › E › EYPT

EyePoint, Inc (EYPT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-05

EyePoint, Inc (EYPT) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 214 employees. Its market capitalization is roughly $30 million. In the fiscal year ended 2025-12-31, EYPT reported $31M in revenue and ($232M) in net income.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Interactive charts & full statements → Open the EYPT valuation workbench →

EYPT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$3M	$31M	$43M	$46M	$41M	$37M	$34M	$20M	$6M	$8M	$2M	$27M	$27M	$3M	$2M	$4M	$5M	$23M	$12M	$3M	$2M
Gross Profit	$1M	$29M	$40M	$41M	$33M	$29M	$29M	$18M	($14M)	$8M	$2M	$27M	$14M	($6M)	($5M)	$4M	$2M	$20M	$12M	$3M	($9M)
Gross Margin %	41.8%	93.4%	91.4%	89.9%	79.9%	77.9%	83.1%	86.8%	-237.9%	100.0%	100.0%	100.0%	54.5%	-175.6%	-226.9%	100.0%	32.4%	85.6%	100.0%	100.0%	-517.0%
Operating Income (EBIT)	($317M)	($243M)	($146M)	($75M)	($100M)	($55M)	($37M)	($48M)	($49M)	($19M)	($22M)	$6M	$6M	($13M)	($12M)	($10M)	($10M)	$9M	($5M)	($25M)	($30M)
Operating Margin %	-11365.2%	-776.0%	-337.1%	-163.1%	-240.6%	-149.6%	-108.3%	-235.0%	-838.8%	-246.4%	-1344.1%	24.2%	24.2%	-388.4%	-561.4%	-294.4%	-201.5%	39.4%	-38.1%	-716.4%	-1707.8%
Net Income	($307M)	($232M)	($131M)	($71M)	($102M)	($58M)	($45M)	($57M)	($53M)	($18M)	($22M)	$6M	$6M	($13M)	($12M)	($25M)	($9M)	$9M	($3M)	($76M)	($85M)
Net Margin %	-10994.7%	-739.4%	-302.4%	-153.8%	-247.0%	-158.1%	-131.8%	-278.9%	-908.0%	-245.2%	-1330.1%	23.9%	23.9%	-384.5%	-555.3%	-704.3%	-173.8%	38.0%	-20.6%	-2176.9%	-4753.1%
EBITDA	($294M)	($229M)	($129M)	($69M)	($97M)	($50M)	($35M)	($48M)	($46M)	($18M)	($21M)	$7M	$7M	($13M)	($11M)	($8M)	($7M)	$12M	($1M)	($25M)	($19M)
Earnings Per Share (EPS)	$-3.74	$-3.17	$-2.32	$-1.82	$-2.74	$-2.03	$-3.54	$-5.44	$-11.50	$-5.23	$-6.81	$2.08	$2.31	$-5.80	$-5.72	$-12.74	$-4.57	$4.79	$-1.38	$-68.55	$-112.81
Shares Outstanding (M)	87M	73M	56M	39M	37M	29M	13M	10M	5M	4M	3M	3M	3M	2M	2M	2M	2M	2M	2M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EYPT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$1M	$1M	$1M	$1M	$5M	$24M	$12M	$11M
Gross Profit	$1M	$0M	$0M	$0M	$5M	$24M	$11M	$10M
Gross Margin %	100.0%	24.1%	39.5%	25.4%	96.9%	96.7%	93.0%	93.0%
Operating Income (EBIT)	($97M)	($87M)	($70M)	($62M)	($62M)	($49M)	($45M)	($33M)
Operating Margin %	-19207.1%	-12532.5%	-11346.0%	-6420.8%	-1166.8%	-199.7%	-390.4%	-311.2%
Net Income	($94M)	($85M)	($68M)	($60M)	($59M)	($45M)	($41M)	($29M)
Net Margin %	-18633.1%	-12188.5%	-10904.7%	-6183.4%	-1114.3%	-184.8%	-357.3%	-279.0%
EBITDA	($93M)	($84M)	($58M)	($59M)	($59M)	($45M)	($41M)	($29M)
Earnings Per Share (EPS)	$-1.09	$-0.99	$-0.81	$-0.85	$-0.85	$-0.65	$-0.64	$-0.54
Shares Outstanding (M)	87M	86M	83M	70M	70M	70M	65M	54M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EYPT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($267M)	($240M)	($126M)	$2M	($65M)	($50M)	($14M)	($57M)	($22M)	($20M)	($16M)	$10M	$10M	($9M)	($9M)	($3M)	$10M	$10M	($5M)	($21M)	($21M)
Capital Expenditures (CapEx)	$4M	$3M	$4M	$3M	$2M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M
Free Cash Flow (FCF)	($271M)	($243M)	($130M)	($2M)	($67M)	($50M)	($15M)	($57M)	($22M)	($21M)	($16M)	$10M	$10M	($9M)	($9M)	($3M)	$10M	$10M	($5M)	($21M)	($23M)
FCF Margin %	-9726.8%	-775.8%	-301.1%	-3.5%	-162.2%	-136.0%	-43.0%	-279.5%	-375.9%	-273.7%	-1014.1%	38.2%	37.8%	-253.8%	-438.9%	-93.7%	199.1%	42.1%	-44.5%	-612.7%	-1260.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EYPT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($62M)	($81M)	($65M)	($59M)	($63M)	($53M)	($36M)	($39M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$1M	$1M	$0M	$0M	$2M
Free Cash Flow (FCF)	($64M)	($82M)	($66M)	($60M)	($64M)	($53M)	($36M)	($41M)
FCF Margin %	-12534.1%	-11716.4%	-10650.5%	-6226.9%	-1196.5%	-218.4%	-312.7%	-385.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EYPT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$228M	$364M	$418M	$355M	$180M	$263M	$92M	$73M	$72M	$19M	$19M	$32M	$32M	$23M	$16M	$21M	$47M	$43M	$39M	$56M	$98M
Cash & Cash Equivalents	$110M	$102M	$100M	$281M	$96M	$179M	$45M	$22M	$39M	$17M	$17M	$15M	$19M	$15M	$7M	$5M	$13M	$16M	$10M	$16M	$4M
Total Liabilities	$62M	$58M	$82M	$89M	$84M	$79M	$73M	$65M	$60M	$5M	$5M	$11M	$9M	$8M	$9M	$7M	$10M	$10M	$17M	$26M	$31M
Total Debt (Short + Long-Term)	$3M	$2M	$1M	$1M	$40M	$37M	$46M	$48M	$18M	$35M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$2M	$2M	$2M	$5M
Total Shareholders' Equity	$166M	$306M	$337M	$266M	$96M	$184M	$19M	$8M	$12M	$13M	$13M	$21M	$23M	$15M	$8M	$14M	$37M	$33M	$22M	$30M	$66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EYPT viewer.

Other Companies in BIOTECHNOLOGY

LRMR · Larimar Therapeutics Inc — $257 million
BBOT · BridgeBio Oncology Therapeutics, Inc. — $210 million
ARTV · Artiva Biotherapeutics, Inc. Common Stock — $205 million
CMPX · Compass Therapeutics Inc. — $142 million
ARGX · argenx NV ADR — $57 billion
RVMD · Revolution Medicines Inc — $42 billion
ONC · BeiGene, Ltd. — $40 billion
RPRX · Royalty Pharma Plc — $38 billion

← EYLD All “E” companies EZA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.